Prnewswire·2026-02-26 11:30Core Insights - The ACHIEVE-3 trial demonstrated that orforglipron significantly outperformed oral semaglutide in reducing A1C levels and promoting weight loss in adults with type 2 diabetes [1][2][4] - Orforglipron 36 mg led to a 2.2% reduction in A1C compared to 1.4% with oral semaglutide 14 mg, and participants on orforglipron lost 19.7 lbs (9.2%) versus 11.0 lbs (5.3%) with oral semaglutide, indicating a 73.6% greater relative weight loss [1][2] - The trial included 1,698 participants and was conducted over 52 weeks, with results published in The Lancet [1][6] Efficacy and Safety - Orforglipron showed clinically meaningful improvements across various cardiovascular risk factors, including cholesterol levels and blood pressure [3][4] - The overall safety profile of orforglipron was consistent with previous studies, with common adverse events being nausea, diarrhea, and vomiting [4][5] - Treatment discontinuation rates due to adverse events were higher for orforglipron (8.7% for 12 mg and 9.7% for 36 mg) compared to oral semaglutide (4.5% for 7 mg and 4.9% for 14 mg) [4] Regulatory and Development Status - Eli Lilly has submitted orforglipron for regulatory approval in over 40 countries, with a potential U.S. action for obesity expected in Q2 2026 [1][5] - The ACHIEVE clinical trial program has enrolled over 6,000 participants across five global registration trials, with further results anticipated later this year [7]